Clinical Trial Update: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study is investigating Benmelstobart in combination with Anlotinib and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart
• Cyclophosphamide (oral metronomic) (cyclophosphamide)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Status: NOT_YET_RECRUITING